AcuCort participates at the Nordic Life Science Days in Malmö, Sweden
Mats Lindfors, CEO of AcuCort AB (Spotlight Stock Market: ACUC)will participate at the Nordic Life Science Days 2019, NLSDays, which is the largest Nordic partnering conference dedicated to the life science industry. The event will take place on September 10-12 in Malmö, Sweden. The annual investor, partnering and networking meeting is expected to bring together over 1,300 participants from the Life Science sector from some 40 countries, primarily the Nordic Region and Europe.
The Nordic Life Science Days has been organized annually since 2013 by SwedenBIO, which is the national non-profit association for the life science industry in Sweden. The conference combines a commercial and scientific program with company presentations and face-to-face meetings between potential collaboration partners. Last year, more than 3,000 partnering meetings took place during NLSDays.
“AcuCort continues to prepare for commercialization of the allergy drug Dexa ODF. AcuCort’s participation in the most recent BIO-Europe conferences in Copenhagen and Vienna has provided positive experiences and several dialogues with potential commercial partners have been initiated. I look forward to the opportunities to further expand and deepen the dialogue with AcuCort's network of possible partners at the Nordic Life Science Days 2019,” says Mats Lindfors, CEO of AcuCort AB.
About the Nordic Life Science Days 2019
For more information about this conference, please visit https://www.nlsdays.com/about-the-event/.
For more information
Mats Lindfors, CEO, AcuCort AB
Mobile: +46 70 790 58 15
E-mail: mats.lindfors@acucort.se
About AcuCort
AcuCort develops and commercializes Dexa ODF, a fast-dissolving oral film containing the well-known glucocorticoid - dexamethasone. Dexa ODF is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of acute allergic reactions, viral croup in children and chemotherapy-induced nausea and vomiting (CINV). The bioequivalence study that forms the basis of the application for marketing approval in Europe is carried out with positive results, which strengthens the assessment that the time until commercialization of Dexa ODF may be relatively short.
AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden.
Learn more at www.acucort.se
Tags: